Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy [Yahoo! Finance]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
On April 1, Zai Lab and Amgen (NASDAQ: AMGN ) entered into a global clinical trial collaboration to evaluate a combination therapy for extensive-stage small cell lung cancer/ES-SCLC. The study will pair Zai Lab's zocilurtatug pelitecan (formerly ZL-1310), an antibody-drug conjugate/ADC targeting DLL3, with Amgen's IMDELLTRA (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager/BiTE. Amgen will sponsor and lead the global Phase 1b study, while Zai Lab Limited (NASDAQ:ZLAB) maintains full ownership of its ADC and provides the clinical supply. The rationale for this dual-targeting strategy lies in the complementary mechanisms of the two therapies. Zocilurtatug pelitecan is designed to deliver a potent cytotoxic payload directly into DLL3-expressing tumor cells, whereas IMDELLTRA activates the patient's own T-cells to attack the same antigen. This combination aims to deepen clinical responses, address potential resistance pathways, and provide better intracranial activity for a
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases [Yahoo! Finance]Yahoo! Finance
- Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesBusiness Wire
- Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas [Yahoo! Finance]Yahoo! Finance
- Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasBusiness Wire
- Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative [Seeking Alpha]Seeking Alpha
ZLAB
Earnings
- 2/26/26 - Miss
ZLAB
Sec Filings
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- ZLAB's page on the SEC website